IL113109A0 - Recombinant viruses, their preparation and their use in gene therapy - Google Patents

Recombinant viruses, their preparation and their use in gene therapy

Info

Publication number
IL113109A0
IL113109A0 IL11310995A IL11310995A IL113109A0 IL 113109 A0 IL113109 A0 IL 113109A0 IL 11310995 A IL11310995 A IL 11310995A IL 11310995 A IL11310995 A IL 11310995A IL 113109 A0 IL113109 A0 IL 113109A0
Authority
IL
Israel
Prior art keywords
gdnf
adenovirus
cell
dna sequence
recombinant
Prior art date
Application number
IL11310995A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL113109A0 publication Critical patent/IL113109A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL11310995A 1994-03-25 1995-03-23 Recombinant viruses, their preparation and their use in gene therapy IL113109A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
IL113109A0 true IL113109A0 (en) 1995-06-29

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11310995A IL113109A0 (en) 1994-03-25 1995-03-23 Recombinant viruses, their preparation and their use in gene therapy

Country Status (14)

Country Link
US (1) US6245330B1 (fi)
EP (1) EP0752004B1 (fi)
JP (1) JPH09510620A (fi)
KR (1) KR100403707B1 (fi)
AT (1) ATE335832T1 (fi)
AU (1) AU704910B2 (fi)
CA (1) CA2184841C (fi)
DE (1) DE69535155T2 (fi)
FI (1) FI963805A (fi)
FR (1) FR2717824B1 (fi)
IL (1) IL113109A0 (fi)
MX (1) MX9604024A (fi)
WO (1) WO1995026408A1 (fi)
ZA (1) ZA952433B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ256018A (en) * 1992-09-25 1997-07-27 Rhone Poulenc Rorer Sa Recombinant adenoviral vectors and their use in directing expression and transcription of selected nucleotide sequences in cells of the central nervous system
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
AU6975198A (en) * 1997-04-15 1998-11-11 University Of Medicine And Dentistry Of New Jersey Cdna for human gdnf and promoter therefor which allows regulated and constitutive expression
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
JP2005514403A (ja) * 2001-12-21 2005-05-19 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ 運動ニューロンに対する標的化逆行性遺伝子送達
AU2004304716B2 (en) * 2003-12-18 2010-05-27 Biomas Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
EP2167688A4 (en) 2007-06-12 2010-07-28 Univ Case Western Reserve TARGETED CELL DEATH
ES2538468T3 (es) 2008-05-20 2015-06-22 Eos Neuroscience, Inc. Vectores para la administración de proteínas sensibles a la luz y métodos para su utilización
EP2731422B1 (en) 2011-07-12 2017-08-09 Mart Saarma miRNA antagonists for use in treating neurodegenerative disorders by increasing expression of GDNF
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
NZ256018A (en) * 1992-09-25 1997-07-27 Rhone Poulenc Rorer Sa Recombinant adenoviral vectors and their use in directing expression and transcription of selected nucleotide sequences in cells of the central nervous system
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
ATE335832T1 (de) 2006-09-15
KR970702373A (ko) 1997-05-13
FI963805A0 (fi) 1996-09-24
ZA952433B (en) 1996-01-15
CA2184841A1 (fr) 1995-10-05
FR2717824B1 (fr) 1996-04-26
MX9604024A (es) 1997-09-30
CA2184841C (fr) 2009-08-18
DE69535155T2 (de) 2007-06-28
AU704910B2 (en) 1999-05-06
WO1995026408A1 (fr) 1995-10-05
US6245330B1 (en) 2001-06-12
KR100403707B1 (ko) 2004-02-11
FI963805A (fi) 1996-09-24
DE69535155D1 (de) 2006-09-21
AU2141195A (en) 1995-10-17
EP0752004A1 (fr) 1997-01-08
FR2717824A1 (fr) 1995-09-29
EP0752004B1 (fr) 2006-08-09
JPH09510620A (ja) 1997-10-28

Similar Documents

Publication Publication Date Title
ZA952433B (en) Recombinant viruses their preparation and their use in gene therapy
AU712775B2 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
Barkats et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
Matsuda et al. Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain
US5707618A (en) Adenovirus vectors for gene therapy
Oligino et al. Vector systems for gene transfer to joints.
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Haase et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action
US6685934B1 (en) Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
KR20060045056A (ko) 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
EP1674108A3 (en) Osteoporosis treatment
Horellou et al. Gene therapy for Parkinson's disease
US20040224409A1 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
Horellou et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease
Robert et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases
US6723315B1 (en) Method for treating amyotrophic lateral sclerosis
AU7154698A (en) Ngf variants
EP0969875B1 (en) Naked dna-mediated gene transfer into medullary motor neurons
Horellou et al. In VivoAdenovirus-Mediated Gene Transfer for Parkinson's Disease
Kojima et al. Construction and Characterization of Adenoviral Vector Expressing Biologically-Active Brain-Derived Neurotrophic Factor
US20220324921A1 (en) Methods and compositions for the treatment of als
Yamano et al. Prospects for gene-based immunopharmacology in salivary glands
AU703793B2 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
US20050069523A1 (en) Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
WO1999036559A1 (en) Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use